Sugi Predict

Sugi Predict / Compounds / SCHEMBL988746

SCHEMBL988746

SCHEMBL988746

COC(=O)c1cc(C)cc(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.53
▸ CA2 P00918 2/20 0.53
▸ ATM Q13315 2/20 0.52
▸ CNR2 P34972 2/20 0.51
▸ KDM4E B2RXH2 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA7 P43166 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ GAA P10253 3/20 0.49
▸ POLB P06746 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ XDH P47989 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl 3,5-Dimethoxybenzoate SCHEMBL204865 0.87 CA1 (0.61) CA1CA2KDM4ETDP1ALDH1A1
SCHEMBL475746 0.87 CA1 (0.61) CA1CA2KDM4ETDP1ALDH1A1
Methyl 3,5-Dimethylbenzoate SCHEMBL334346 0.85 CNR2 (0.66) CA1CA2ATMCNR2KDM4E
SCHEMBL70232 0.85 ATM (0.61) CA1CA2ATMCNR2KDM4E
SCHEMBL9967360 0.85 KMT2A (0.63) ATMKDM4EALDH1A1GAAPOLB
SCHEMBL2781665 0.83 CNR2 (0.47) CA1CA2ATMCNR2KDM4E
SCHEMBL14107665 0.83 MEN1 (0.49) CA1CA2ATMCNR2KDM4E
SCHEMBL18210850 0.82 CNR2 (0.54) CA1CA2ATMCNR2KDM4E
SCHEMBL16957372 0.82 KAT6A (0.49) CA1CA2ATMCNR2KDM4E
SCHEMBL26151409 0.82 CNR2 (0.46) CA1CA2ATMCNR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273880-B2 Pyrazole compounds with inhibitory activity against ROS kinase KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-09-25 — — US claimed
US-20110015395-A1 PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-01-20 — — US claimed
EP-3250571-B1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2022-11-30 — — EP disclosed
CN-107531692-B Therapeutic compounds and uses thereof 基因泰克公司 2020-12-25 — — CN disclosed
US-10202378-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-02-12 — — US disclosed
US-10202378-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-02-12 — — US disclosed
US-20180022713-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2018-01-25 — — US disclosed
US-20180009805-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-01-11 — — US disclosed
US-20180009805-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-01-11 — — US disclosed
US-20170360785-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-12-21 — — US disclosed
EP-3250571-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2017-12-06 — — EP disclosed
US-20110015395-A1 PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2011-01-20 — — US disclosed
EP-2197876-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS Glaxosmithkline LLC (US) 2010-06-23 — — EP disclosed
EP-2044063-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Astra Zeneca AB (SE) 2009-04-08 — — EP disclosed
WO-2009032667-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — WO disclosed
WO-2009032667-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — WO disclosed
EP-2024353-A2 PYRAZOLE COMPOUNDS Pfizer Products Inc. (US) 2009-02-18 — — EP disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 — — WO disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 — — US disclosed
WO-2007105058-A2 PYRAZOLE COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360785-A1 PYRIMIDINE FGFR4 INHIBITORS FGFR4, FGFR1, FGFR3 CA1 4832/4885CA2 4433/4885ATM 990/4885
US-20110015395-A1 PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE ROS1, PDPK1, MAP3K19 CA1 4596/4885CA2 2649/4885ATM 311/4885
US-10202378-B2 Therapeutic compounds and uses thereof TAF1, TAF1L, TAF1B CA1 3912/4885CA2 3829/4885ATM 3321/4885
US-20180022713-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 CA1 4107/4885CA2 3325/4885ATM 4494/4885
US-20180009805-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF TAF1, TAF1L, TAF1B CA1 3912/4885CA2 3829/4885ATM 3321/4885
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 CA1 4191/4885CA2 4162/4885ATM 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback